

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND TEMPORARY NON-COMPLIANCE WITH RELEVANT LISTING RULES

The board (the “**Board**”) of directors (the “**Director(s)**”) of TYK Medicines, Inc (the “**Company**”) announces that Mr. ZHANG Senquan (“**Mr. Zhang**”) has tendered his resignation as an independent non-executive Director of the Company (“**INED**”) with effect from September 15, 2025 in order to devote more time to his other business endeavors. Upon his resignation, Mr. Zhang ceased to be the chairman of the audit committee of the Board, a member of each of the remuneration and appraisal committee and the nomination committee of the Board. Mr. Zhang has confirmed that he has no disagreement with the Board and the Company, and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude and appreciation to Mr. Zhang for his valuable contributions to the Board during his tenure of services.

TEMPORARY NON-COMPLIANCE WITH REQUIREMENTS UNDER THE LISTING RULES

Following the resignation of Mr. Zhang, the Company is not in compliance with (i) Rule 3.10(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) which stipulate that at least one of the independent non-executive directors must have appropriate professional qualifications or accounting or related financial management expertise; (ii) Rule 3.21 of the Listing Rules which stipulate that a listed issuer must establish an audit committee comprising a minimum of three members, at least one of whom is an independent non-executive director with appropriate professional qualifications or accounting or related financial management expertise as required under Rule 3.10(2) of the Listing Rules, and the majority of which must be INEDs; (iii) Rule 3.25 of the Listing Rules which stipulate that the remuneration committee must comprise a majority of INEDs; and (iv) Rule 3.27A of the Listing Rules which stipulates that a listed issuer must establish a nomination committee with a majority of INEDs.

In order to comply with the Listing Rules, the Company will make its best endeavor to identify suitable candidate to fill the casual vacancy on the Board for the position of INED as soon as possible within three months from the effective date of resignation of Mr. Zhang pursuant to Rules 3.11 and 3.23 of the Listing Rules. Further announcement will be made by the Company as and when appropriate.

By order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, September 15, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.